Mazdutide Phase 3 trial (NCT05628311)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 319
- actual
- Start
- 6 Jan 2023 (actual)
- Primary completion
- 25 Oct 2023 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| IBI362 4.0 mg | Experimental | Drug: IBI362 | ①2mg, subcutaneously (SC), once a week\* 4weeks; ②4mg, SC, once a week\* 44weeks. |
| IBI362 6.0 mg | Experimental | Drug: IBI362 | ①2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 4weeks; ③6mg, SC, once a week\* 40weeks. |
| placebo | Placebo comparator | Other: placebo | * placebo, SC, once a week\* 24weeks; * 2mg, SC, once a week\* 4weeks; * 4mg, SC, once a week\* 4weeks; * 6mg, SC, once a week\* 16weeks. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| HbA1c change from baseline at week 24 | Baseline, 24 weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Proportion of subjects with HbA1c<7.0% at week 24 | Baseline, 24 weeks |
| Safety, Incidence and severity of adverse events and correlation with study drug; | Baseline to 52 weeks |
| Time to peak plasma concentration (Tmax) | Baseline to 52 weeks |
| Time to peak plasma concentration (Cmax) | Baseline to 52 weeks |
| area under curve (AUC) | Baseline to 52 weeks |
| volume distribution (V) | Baseline to 52 weeks |
| half-life (half-life, T1/2) | Baseline to 52 weeks |
| clearance rate (clearance, CL) | Baseline to 52 weeks |
| To assess changes in PD parameters fasting insulin at different time points before and after administration. | Baseline to 52 weeks |
| To assess changes in PD parameters fasting C-peptide at different time points before and after administration. | Baseline to 52 weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and ExerciseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.